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Abstract 
Background: sTREM-1 (soluble triggering receptor expressed on myeloid cells-1) is a 
novel inflammatory marker that may be of clinical use in cystic fibrosis (CF). 
Dysregulation of the TREM pathway has been demonstrated in other inflammatory 
diseases and modulation in animal models has therapeutic benefit. We hypothesised 
that sTREM-1 could act as a biomarker of disease in cystic fibrosis. 
Methods: Plasma from seventeen patients with CF (stable and pre and post 
pulmonary exacerbation) and eight healthy volunteers was analysed for sTREM-1 and 
proteases (matrix metalloproteinase-8 (MMP-8), MMP-9 and human neutrophil 
elastase HNE). 
Results: sTREM-1 levels were elevated in stable CF subjects compared to controls (148 
pg/ml (130-160) [median(IQR)] vs.87(55-118) (p<0.01))  but were not further 
increased during pulmonary exacerbation nor decreased after antibiotic treatment in 
CF. Protease levels were increased in CF plasma compared to controls: MMP-8 = 
3.1ng/ml (1.5-7.6) vs 0.3 (0.18-0.53) (p<0.01) (Wilcoxon)); MMP-9 = 170ng/ml (124-
282) vs 49 (39-90) (p<0.01); HNE = 30.2 ng/ml (22.7-30.9)vs17.5 (11.2-22.2) (p<0.05). 
sTREM-1 correlated positively with protease levels lnMMP-8 r2=0.55 (p=0.08), lnMMP-
9 r2=0.61(p<0.05), lnHNE r2=0.35(p<0.05). 
Conclusions: sTREM-1 is constitutively elevated in CF and positively correlates with 
protease levels. Modulation of this pathway may be of therapeutic benefit to patients 
with CF. 
  
Introduction 
Cystic Fibrosis (CF) lung disease is characterised by airway inflammation and infection 
although the mechanism of initiation and propagation remains unclear1,2. Airway 
sampling reveals high levels of inflammatory mediators and abundant neutrophils3,4. 
These neutrophils and those found in the systemic circulation are abnormal in 
cytokine production and response to stimuli5-7. 
 
Triggering receptor expressed on myeloid cells-1 (TREM-1) is an activating surface 
receptor expressed at high levels on neutrophils infiltrating tissues infected with 
extracellular bacteria8.  Activation of TREM-1 amplifies the inflammatory response - a 
key step in the development of systemic sepsis. Several studies in non-CF pulmonary, 
sepsis and systemic diseases have implicated a role for TREM-1. For example, a soluble 
portion of the surface bound receptor (sTREM-1) is shed/cleaved from activated 
phagocytes and elevated levels of this protein are found in the circulation of patients 
with sepsis and the lower airways of those with in ventilator associated 
pneumonia9,10.  Furthermore sTREM-1 is of prognostic value in patients with 
community acquired pneumonia11 and is positively correlated with severity of disease 
in patients with COPD12. Blockade of the TREM-1 pathway in animal studies provides 
protection against sepsis even after the initiating event13 suggesting it may be a 
possible therapeutic target.  
 
We hypothesised that pulmonary inflammation in CF would lead to increased sTREM-
1 in circulating blood and that sTREM-1 would be an easily measured surrogate 
measure of disease activity. Matrix metalloproteinases (MMPs) have been 
demonstrated to cleave TREM from human stimulated monocytes 14 and have been 
shown to be elevated in airway secretions15 and associated with exacerbations in CF16. 
We also hypothesised that MMPs may be responsible for cleaving sTREM-1 from the 
surface of cells in CF in vivo and explored the association of sTREM-1 and MMPs in 
patients with CF and healthy control subjects. 
 
  
Materials & Methods 
Venous blood samples were obtained from seventeen adults diagnosed with CF (on 
the basis of a known CF genotype and/or a positive sweat test chloride >60mml/L) and 
eight healthy controls. 
 
Venous samples were obtained from eight patients requiring intravenous antibiotics 
for a physician defined pulmonary exacerbation. An initial blood sample was taken 
prior to administration of the first dose of intravenous antibiotics and again at 
fourteen (+/-two) days. A ‘stable’ CF group consisted of nine patients who had no 
symptoms of exacerbation for at least four weeks. Healthy controls consisted of eight 
volunteers who had no known systemic disease and no coryzal symptoms 
(demographics in Table 1). The local Research Ethics Committee approved the study 
(REC ref. No. 08/H0406/110) and all participants gave informed consent.  
  
All blood samples were processed within thirty minutes of harvesting and plasma 
stored at -80oC prior to analysis. Analysis for sTREM-1 and proteases was performed 
in triplicate using commercially available R&D Systems Quantikine ELISA kits.  
 
Statistical analysis was performed using Stata v11 (Texas). Data were inspected for 
normality both visually and using the Shapiro-Wilk test. Where values were not 
normally distributed, data were log transformed or non-parametric tests were 
performed. A p value <0.05 was considered significant. In the statistical analysis of 
plasma sTREM-1 levels, we initially compared healthy controls to individuals with 
stable CF. We went on to compare individuals with stable CF to those who were 
experiencing an exacerbation both at initiation and after antibiotics separately. 
  
Results 
sTREM-1 levels are elevated in stable CF subjects compared to 
controls but are not increased during CF exacerbations nor 
decreased after antibiotic treatment in CF 
The levels of sTREM-1 found in stable CF patients were significantly higher than that 
in healthy controls 148 pg/ml (130-160) [median(IQR)] vs.87(55-118) (p<0.01 
(Wilcoxon)). The sTREM-1 levels in CF patients during an exacerbation were also 
significantly higher than healthy controls before treatment 142 pg/ml (108-177) 
p<0.05 and after treatment 130 pg/ml (100-193) p<0.05 but not significantly different 
to stable CF patients. The levels did not change significantly (paired Wilcoxon) after 
systemic antibiotic therapy 142 pg/ml (108-177) vs. 130(100-193) see Fig 1. sTREM-
1 was not found to be correlated with FEV1 nor was change in sTREM-1 
correlated to change in FEV1 during the treatment of exacerbations. 
 
Protease levels are increased in CF serum compared to controls 
Protease levels in the stable CF group were significantly higher than in the control 
group of healthy subjects MMP-8 = 3.1ng/ml (1.5-7.6) vs. 0.3 (0.18-0.53) (p<0.01) 
(Wilcoxon)); MMP-9 = 170ng/ml (124-282) vs. 49 (39-90) (p<0.01) (Wilcoxon); HNE = 
30.2 ng/ml (22.7-30.9)vs17.5 (11.2-22.2) (p<0.05) (Wilcoxon) see Fig 2. 
 
sTREM-1 correlates with protease levels 
The relationship of sTREM-1 and proteases in the nine stable patients with CF and the 
eight healthy controls group was explored. Data from the Healthy Control and Stable 
Cystic Fibrosis groups were combined to look at the physiological correlation between 
the two molecules. (We combined the groups as numbers were insufficient to look at 
either group alone with any statistical power.) The data for protease levels were log 
transformed. There were correlations between MMP-9, HNE and sTREM-1 (ln MMP-8 
r2=0.55 (p=0.08), lnMMP-9 r2=0.61(p<0.05), lnHNE r2=0.35(p<0.05)) see Fig3. The 
levels of sTREM-1 and proteases were not correlated in the samples taken from 
patients suffering exacerbations.
Discussion 
This study demonstrated a constitutive elevation of an important inflammatory 
regulator (sTREM-1) in the plasma of CF patients. There was no significant increase in 
the level of sTREM-1 during a pulmonary exacerbation and treatment with 
intravenous antibiotics did not significantly reduce levels. The data also show a 
positive correlation between sTREM-1 and plasma proteases.  
 
The study had a number of limitations. This was a small pilot study powered to show 
a difference in levels of sTREM-1 between healthy controls and patients with CF so the 
further conclusions, notably negative ones such as the impact of antibiotics on levels 
of sTREM-1 need to be interpreted cautiously. The healthy controls were not age and 
sex matched to the CF groups and smoking histories from participants were not taken. 
A further confounding factor may be the medications taken by patients with CF that 
may directly impact on the sTREM-1 pathway17. The difficulty of defining an 
exacerbation in CF is a recurring topic and in this study we used the pragmatic 
approach of a physician-based diagnosis as this is applicable to standard clinical 
practice. A further limitation to interpretation is the complex nature of protease/anti-
protease relationships and active and inactive isoforms thus our use of the 
measurement of total protease level via ELISA rather than a more complex 
methodology to allow measurement of activity may not provide the whole picture. 
 
This is the first study to demonstrate an elevation of sTREM-1 in the plasma of patients 
with CF compared to healthy controls. There are very limited data on sTREM-1 in lung 
secretions in CF. A small pediatric study compared levels of sputum sTREM-1 in 
patients with CF (n=17) to patients with HIV-related bronchiectasis (n=26) and found 
the sputum levels of sTREM-1 to be significantly higher in the HIV-related 
bronchiectasis group. Although this study analysed sputum rather than serum sTREM-
1, it also found no significant elevation of sTREM-1 associated with pulmonary 
exacerbations in the CF group (n=6).22 This mimics the findings of Radsak and 
colleagues who demonstrated an increase in the levels of sTREM-1 in the sera of 
patients with COPD that was correlated to disease severity12 and the demonstration 
of its utility as a prognostic indicator in community acquired pneumonia11. The 
mechanism behind this increase in sTREM-1 may be through a number of processes: 
an increase in the number of phagocytic cells from which sTREM-1 is cleaved, an 
increase in expression of TREM-1 on the surface of these cells, an increase in the 
cleavage from the cells, a decrease in binding of sTREM-1 or an alteration in the 
metabolism or excretion of sTREM-1. Patients with CF have increased numbers of 
inflammatory cells in the lungs from which sTREM-1 may be cleaved and also have 
increased levels of MMPs in their airways18 and serum16. 
 
We also demonstrate a positive correlation between MMPs and sTREM-1 in stable 
subjects. This finding was not seen in patients undergoing an exacerbation. As a pilot 
study, while the data are limited and associations may be a chance finding, the 
observations are worthwhile considering in the context of the literature.  
 
The association reported here contrasts with the in-vitro work of del Fresno and 
colleagues. This group explored the nature of TREM-1 expression on monocytes 
harvested from patients with CF (and COPD) and noted that TREM-1 was down-
regulated in comparison with monocytes from healthy volunteers and there was also 
a failure of the CF derived cells to up-regulate TREM-1 in response to challenge with 
lipopolysaccharide (LPS)19. However, when levels of serum sTREM-1 from patients 
with CF (n=20) were compared with healthy controls no significant differences were 
found. The levels of sTREM-1 seen in the healthy controls in the del Fresno group 
appear to be higher than observed in this study and the reason for this is unclear. 
Control groups in previous studies have had varying levels of circulating sTREM-1 and 
those seen in our study are similar to non bacteremic patients in a pneumonia study 
(n=11) 20 and patients with inflammatory bowel disease21.  
 
MMPs have been shown to cleave TREM-1 from monocytes in vitro14 and our data 
support this as a putative mechanism with higher levels seen in CF compared to 
healthy controls. MMPs have been shown to be found in elevated concentrations and 
activity in airway secretions from patients with CF. The relative activity of MMPs is a 
balance between the protease and tissue inhibitor which has also been shown to be 
dysregulated in exacerbations.23 This dysregulation has been shown to be attenuated 
by a reduction in proteolytic activity when MMP inhibitors are added to CF sputum.24 
The close relationship demonstrated between sTREM-1 and MMPs in this clinical in 
vivo setting supports the in vitro observations of Gomez-Pina et al14 that an inhibitor 
of MMPs (Ilomostat) can block the removal of TREM-1 from monocytes stimulated 
with LPS.  
 
Animal studies of infection have shown promise in therapeutic manipulation of the 
TREM-1 pathway. A synthetic peptide derivative of sTREM-1 used in P.aeruginosa 
pneumonia in rats attenuated the inflammatory response not only in the lung but at 
a systemic level (reduction in TNF- and IL-1)25.  This improved survival (compared 
with TNF- blockade which decreased survival) suggesting that this is an uncontrolled, 
detrimental inflammatory response. Murine studies have also shown blockade of the 
TREM-1 pathway (by a fusion protein of murine sTREM-1 extracellular domain and 
human immunoglobulin-gamma Fc portion [msTREM-1/IgG1]) provides protection 
against sepsis even after the initiating event 13.  
 
In summary, these suggest dysregulation of the TREM-1 pathway in CF. While these 
data suggest the role for sTREM-1 as a biomarker of disease status in CF is limited, the 
constitutive elevation suggests this pathway as a potential future therapeutic target. 
Whether the constitutive elevation is due to increased cleavage of TREM from the cell 
surface through elevated protease levels or through increased trafficking of TREM to 
the cell surface is unclear. Inhibition of the MMPs which cleave sTREM-1 from 
neutrophils may also be worth exploring as a therapeutic target.  
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Table 1. Baseline participant demographic data 
 Control “Stable”CF “Exacerbating"CF 
Age 
(Median, IQR) 
31.5 
(30.0-35.3) 
28.0 
(27.0-31.0) 
25.0 
(21.3-28.3) 
Male/female 4/4 5/4 3/5 
Weight 
(Median, IQR) 
67.5 
(58.8-76.3) 
59.0 
(51.0-65.0) 
58.0 
(54.8-66.5) 
FEV L/min 
(Median, IQR) 
 1.96 
(1.43-2.53) 
1.64 
(1.27-2.26) 
FEV1 %pred 
(Median, IQR) 
 58 
(45-72) 
41 
(36-62) 
 
Figure 1. Plasma levels of sTREM-1 are increased in Cystic Fibrosis 
but do not vary during pulmonary exacerbation (**= p<0.01) 
 
 
 
 
Figure 2. Plasma MMP-8, MMP-9 & Human neutrophil elastase are 
higher in Cystic Fibrosis than Healthy Controls (*=p<0.05, **=p<0.01) 
 
 
 
Figure 3 Plasma MMP-8, MMP-9 & Human neutrophil elastase vs. 
sTREM-1 in stable Cystic Fibrosis and Healthy Controls 
Open circles are healthy controls; closed circles are stable Cystic Fibrosis 
 
 
 
 
